HRP20120676T1 - Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije - Google Patents
Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije Download PDFInfo
- Publication number
- HRP20120676T1 HRP20120676T1 HRP20120676TT HRP20120676T HRP20120676T1 HR P20120676 T1 HRP20120676 T1 HR P20120676T1 HR P20120676T T HRP20120676T T HR P20120676TT HR P20120676 T HRP20120676 T HR P20120676T HR P20120676 T1 HRP20120676 T1 HR P20120676T1
- Authority
- HR
- Croatia
- Prior art keywords
- thiomyosin
- treatment
- ptx3
- gancyclovir
- alone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06113401 | 2006-05-02 | ||
| PCT/EP2007/053574 WO2007128647A1 (en) | 2006-05-02 | 2007-04-12 | USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120676T1 true HRP20120676T1 (hr) | 2012-09-30 |
Family
ID=36658736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120676TT HRP20120676T1 (hr) | 2006-05-02 | 2007-04-12 | Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8337828B2 (https=) |
| EP (1) | EP2012816B1 (https=) |
| JP (1) | JP5441685B2 (https=) |
| KR (1) | KR101380360B1 (https=) |
| CN (1) | CN101437535B (https=) |
| AU (1) | AU2007247292B2 (https=) |
| BR (1) | BRPI0711136A2 (https=) |
| CA (1) | CA2649063C (https=) |
| CY (1) | CY1113277T1 (https=) |
| DK (1) | DK2012816T3 (https=) |
| ES (1) | ES2389452T3 (https=) |
| HR (1) | HRP20120676T1 (https=) |
| MX (1) | MX2008013872A (https=) |
| PL (1) | PL2012816T3 (https=) |
| PT (1) | PT2012816E (https=) |
| RS (1) | RS52377B (https=) |
| SI (1) | SI2012816T1 (https=) |
| WO (1) | WO2007128647A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| US8829173B2 (en) * | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| WO2010129947A2 (en) * | 2009-05-08 | 2010-11-11 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| US20140213506A1 (en) * | 2011-02-09 | 2014-07-31 | Cynthia W. TUTHILL | Thymosin alpha peptide for preventing, reducing the severity of, and treating infection |
| ES2786051T3 (es) | 2012-10-25 | 2020-10-08 | Tocagen Inc | Vector retroviral con casete de mini-promotor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6106868A (en) * | 1990-08-24 | 2000-08-22 | The Board Of Governors Of Wayne State University | Method for the treatment of hepatitis |
| TW224053B (https=) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| CN1072961C (zh) * | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
| US6200952B1 (en) * | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
| US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| WO1998018491A1 (en) * | 1996-10-28 | 1998-05-07 | BURGSTINER, Jacqueline, Cook | Methods and compositions for dietary supplementation |
| US5939423A (en) * | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| US6288033B1 (en) * | 1998-09-25 | 2001-09-11 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir |
| IT1317927B1 (it) | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
| IT1317930B1 (it) | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| US20040198655A1 (en) | 2001-08-03 | 2004-10-07 | Alberto Mantovani | Use of long pentraxin ptx3 for treating female infertility |
| WO2003035111A1 (en) * | 2001-10-24 | 2003-05-01 | Sciclone Pharmaceuticals, Inc. | Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
| JP2006524704A (ja) * | 2003-04-23 | 2006-11-02 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | アルファチモシンペプチドによる呼吸器ウイルス感染の治療または予防 |
| ITRM20030596A1 (it) | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
-
2007
- 2007-04-12 RS RS20120363A patent/RS52377B/sr unknown
- 2007-04-12 EP EP07728041A patent/EP2012816B1/en active Active
- 2007-04-12 KR KR1020087029405A patent/KR101380360B1/ko not_active Expired - Fee Related
- 2007-04-12 DK DK07728041.0T patent/DK2012816T3/da active
- 2007-04-12 PT PT07728041T patent/PT2012816E/pt unknown
- 2007-04-12 WO PCT/EP2007/053574 patent/WO2007128647A1/en not_active Ceased
- 2007-04-12 HR HRP20120676TT patent/HRP20120676T1/hr unknown
- 2007-04-12 SI SI200730976T patent/SI2012816T1/sl unknown
- 2007-04-12 ES ES07728041T patent/ES2389452T3/es active Active
- 2007-04-12 CA CA2649063A patent/CA2649063C/en not_active Expired - Fee Related
- 2007-04-12 BR BRPI0711136-3A patent/BRPI0711136A2/pt not_active IP Right Cessation
- 2007-04-12 US US12/298,643 patent/US8337828B2/en not_active Expired - Fee Related
- 2007-04-12 AU AU2007247292A patent/AU2007247292B2/en not_active Ceased
- 2007-04-12 JP JP2009508294A patent/JP5441685B2/ja not_active Expired - Fee Related
- 2007-04-12 MX MX2008013872A patent/MX2008013872A/es active IP Right Grant
- 2007-04-12 PL PL07728041T patent/PL2012816T3/pl unknown
- 2007-04-12 CN CN2007800159035A patent/CN101437535B/zh not_active Expired - Fee Related
-
2012
- 2012-08-23 CY CY20121100756T patent/CY1113277T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101437535A (zh) | 2009-05-20 |
| KR20090007621A (ko) | 2009-01-19 |
| BRPI0711136A2 (pt) | 2011-08-30 |
| PT2012816E (pt) | 2012-08-17 |
| CA2649063C (en) | 2014-11-25 |
| CN101437535B (zh) | 2013-01-30 |
| RS52377B (sr) | 2012-12-31 |
| JP2009535373A (ja) | 2009-10-01 |
| DK2012816T3 (da) | 2012-09-03 |
| AU2007247292B2 (en) | 2012-04-05 |
| ES2389452T3 (es) | 2012-10-26 |
| JP5441685B2 (ja) | 2014-03-12 |
| US8337828B2 (en) | 2012-12-25 |
| CA2649063A1 (en) | 2007-11-15 |
| SI2012816T1 (sl) | 2012-09-28 |
| CY1113277T1 (el) | 2016-04-13 |
| AU2007247292A1 (en) | 2007-11-15 |
| MX2008013872A (es) | 2008-11-14 |
| WO2007128647A1 (en) | 2007-11-15 |
| HK1128622A1 (en) | 2009-11-06 |
| PL2012816T3 (pl) | 2012-11-30 |
| KR101380360B1 (ko) | 2014-04-09 |
| US20090275508A1 (en) | 2009-11-05 |
| EP2012816B1 (en) | 2012-06-27 |
| EP2012816A1 (en) | 2009-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120676T1 (hr) | Uporaba tiomiozina 1, samog ili u kombinaciji s ptx3 ili ganciklovirom, za liječenje citomegalovirusne infekcije | |
| CL2011000742A1 (es) | Virus herpes bovino 1 (bhv-1) que posee modificaciones de ul49.5 y al menos un gen adicional que codifica una proteina que puede suprimir el sistema inmune de un huesped infectado, que se selecciona a partir de ul41,us4, y su combinacion. | |
| PH12015500773B1 (en) | Methods and compositions for live attenuated viruses | |
| CL2013001471A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
| WO2009060429A3 (en) | Compositions for conferring tolerance to viral disease in social insects, and the use thereof | |
| HRP20241701T1 (hr) | Modificirani nukleozidi, nukleotidi i nukleinske kiseline i njihova uporaba | |
| ATE503769T1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
| MY151062A (en) | Pseudoinfectious flavivirus and uses thereof | |
| MX341842B (es) | Virus de la influenza capaces de infectar canidos y usos de los mismos. | |
| WO2009025743A3 (en) | Use of trail compositions as antiviral agents | |
| WO2008045120A3 (en) | Transgenic mouse lines expressing human ace2 and uses thereof | |
| HRP20110713T1 (hr) | Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830 | |
| ATE547118T1 (de) | Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung | |
| MX2010001849A (es) | Depsipeptidos ciclicos. | |
| EP2199391A4 (en) | LATEN INFECTION TO HERPESVIRUS INVOLVED FACTOR AND USE THEREOF | |
| BRPI0921424A2 (pt) | vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica. | |
| BRPI0922701A8 (pt) | Método para intensificar atividade viral mediada por interferon em um animal de companhia | |
| PH12013501373B1 (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
| EP2489739A3 (en) | Materials and methods for respiratory disease control in canines | |
| ATE549031T1 (de) | Impfstoffzusammensetzung zur prävention von cmv- infektionen | |
| Ma et al. | Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae | |
| BR0310046A (pt) | Atenuação de metapneumovìrus | |
| AR094810A1 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| BRPI0600195A (pt) | composição aquosa | |
| DK1993585T3 (da) | Anvendelse af den lange pentraxin PTX3 til forebyggelse eller behandling af virussygdomme |